Hemic and Lymphatic Diseases

593 trials 238 recruiting

Filter these 593 trials by phase, country and sponsor.

Open in Search →

Sequential Gilteritinib in Combination with Venetoclax and Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mut… Recruiting

2023-507878-41-00 Acute myeloid leukemia 4 2025-04-25
A Worldwide Study Testing the New Drug Olverembatinib for Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2) Recruiting

2024-511495-32-00 Chronic Phase Chronic Myeloid Leukemia 5 2025-04-16
Anticoagulation with apixaban in venous malformations Recruiting

2024-511930-11-00 Venous malformation 4 2025-04-15
Addition of sulfalasazine to chemotherapy for the treatment of AML in the elderly Recruiting

2024-513084-38-00 Recently diagnosed non favorable Acute Myeloid Leukemia 9 2025-04-15
A trial to learn how well surovatamig (AZD0486) works and how safe it is in adults with certain blood cancers Recruiting

2023-505789-27-00 Relapsed or Refractory Non-Hodgkin Lymphoma 4 2025-04-14
Clinical trial with a combination of Rituximab and Golcadomide as first line therapy for older frail patients with Diffuse Large B-cells non… Recruiting

2023-506206-38-00 Diffuse Large B-cells non-Hodgkin Lymphoma 4 2025-04-09
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell L… Recruiting

2022-501489-24-00 First-line treatment of adult subjects with high-risk l 5 2025-03-28
Ziftomenib in combination with chemotherapy for children with relapsed/refractory acute leukemia Recruiting

2023-505262-28-00 Acute Myeloid Leukemia 3 2025-03-24
Efficacy of Venetoclax in combination with Rituximab in Waldenström’s Macroglobulinemia Recruiting

2022-500574-34-00 Waldenström’s Macroglobulinemia 4 2025-03-21
A Phase I/II with Ruxolitinib in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA-MED) Recruiting

2024-515252-20-00 Myelofibrosis (MF) unresponsive to JAK inhibitors 9 2025-03-14
An Open-Label Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants with PNH Who Have Clinically Sig… Recruiting

2024-511795-32-00 Paroxysmal Nocturnal Hemoglobinuria 5 2025-02-11
A phase II, multicenter, open-label study evaluating Glofitamab in combination with Venetoclax plus Zanubrutinib or Venetoclax alone in subj… Recruiting

2023-506706-40-00 Mantle-Cell Lymphoma 10 2025-02-11
Multicentric Phase 1 Study With Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) or CPX-351 … Recruiting

2022-502585-25-00 Adult patients with adverse Risk Acute Myeloblastic Leu 3 2025-02-06
Eltrombopag for the treatment of thrombocytopenia due to low - and intermediate risk myelodysplastic syndromes. Recruiting

2024-520133-72-00 Myelodysplastic syndromes 4 2025-02-05
EWALL-PH-03: An open label, 2-arm, Randomised phase II study to Compare the Safety and Efficacy of Ponatinib plus Chemotherapy with Imatinib… Recruiting

2023-505330-95-01 Blood cancer 4 2025-01-30
Application of the autologous CAR T cells (Tarcidomgen Kimleucel) in the treatment of refractory and relapsed CD19+ B cell neoplasms Recruiting

2025-520653-37-00 Application of the autologous CAR T cells (Tarcidomgen 1 2025-01-30
Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to Myelodysplastic Syndromes with del5q refractory/resistant/intolerant … Recruiting

2024-519310-31-00 Anemia due to MDS with del5q with IPSS-R very low, low, 4 2025-01-27
IMMUNOTHERAPY WITH DIFFERENTIATED T CELLS, ADULTS, AUTOLOGOUS, FROM PERIPHERAL BLOOD, SELECTED BY CD62L EXPRESSION, EXPANDED AND TRANSDUCED … Recruiting

2024-519790-19-00 Relapsed/refractory large B-cell non-Hodgkin lymphoma, 7 2025-01-24
A phase 2A pilot study to assess the safety and efficacy of eltanexor in relapsed/refractory NPM1-mutated acute myeloid leukemia Recruiting

2024-514724-16-01 Acute Myeloid Leukemia 4 2025-01-14
A research study looking at long-term treatment with etavopivat in people with sickle cell disease or thalassaemia Recruiting

2024-510805-27-00 Sickle Cell Disease and Thalassaemia 5 2025-01-09
Takeda Brentuximab; Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-posit… Recruiting

2024-511151-18-01 Patients with stage II-IV high risk diffuse large B-cel 3 2025-01-02
Acalabrutinib Monotherapy vs Investigator’s Choice of Treatment in Patients with Chronic Lymphocytic Leukaemia and Moderate to Severe Cardia… Recruiting

2023-510147-37-00 Chronic Lymphocytic Leukaemia and Moderate to Severe Ca 6 2024-12-18
Free regimen of Dexamethasone as initial therapy for advanced relapsed/refractory multiple myeloma: an open-label randomized, non-inferiorit… Recruiting

2024-510981-18-00 Multiple Myeloma Multiple myeloma (MM) is a B cell mali 5 2024-12-12
A trial to learn if AZD5492 is safe and works alone and in combination with other cancer treatments in adults with B-cell blood cancers. Recruiting

2024-511099-34-00 B-Cell Malignancies 1 2024-12-12